Acute Heart Failure in a Patient with Acute Myeloid Leukemia following Daunorubicin Treatment: a Case ReportLawrence Druhan*, Omotayo Fasan and Olivia R. Copelan
Levine Cancer Institute - Carolinas HealthCare System, Department of Hematologic Oncology and Blood Disorders, 1021 Morehead Medical Drive, Charlotte, NC 28204, USA
- *Corresponding Author:
- Lawrence Druhan, PhD
1Levine Cancer Institute - Carolinas HealthCare System
Department of Hematologic Oncology and Blood Disorders
1021 Morehead Medical Drive, Charlotte, NC 28204, USA
E-mail: [email protected]
Received date: May 11, 2015; Accepted date: June 02, 2015; Published date: June 10, 2015
Citation: Druhan L, Fasan O, Copelan OR (2015) Acute Heart Failure in a Patient with Acute Myeloid Leukemia following Daunorubicin Treatment: a Case Report. J Leuk 3:185. doi:10.4172/2329-6917.1000185
Copyright: © 2015 Druhan L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Heart failure following anthracycline treatment is usually chronic, irreversible, and related to life time dose. We present a patient with Acute Myeloid Leukemia (AML) who developed Heart failure soon after dose intensified treatment with daunorubicin, with a decrease in Ejection Fraction (EF) from 60% to as low as 10% six months after initial treatment. The patient was managed medically, his EF increased to greater than 50%. With this improvement in EF the patient was treated with reinduction chemotherapy and proceeded to hematopoietic stem cell transplantation. Following transplantation, the patient again developed heart failure, which contributed to his death. While anthracycline dose intensification can be effective in the treatment of AML, there is a risk of heart failure which requires further study.